肿瘤标志物在非小细胞肺癌诊断中的价值

采用免疫电化学发光分析方法，于手术前后联合检测临床各期不同病理类型的104例非小细胞肺癌患者和17例肺部良性占位性病变患者外周血中的癌胚抗原、神经元特异性烯醇化酶（NSE）和细胞角蛋白19片段（CYFRA21—1）的变化。手术前3种血清标志物的平均水平非小细胞肺癌组明显高于肺良性疾病组，组间差异有统计学意义（分别为t=7．930、5．568、6．110，P〈0．05）；手术后3种标志物的平均水平非小细胞肺癌组略高于肺良性疾病组，两组间差异无统计学意义（分别为t=-0．034、1．242、0．691，P〉0．05）；非小细胞肺癌患者在手术前后癌胚抗原、NSE和CYFRA21-1的平均水平差异有统计学意义（分别为t=5．419、4．722、5．779，P〈0．05）；肺良性疾病患者在手术前后3种标志物的平均水平差异无统计学意义（分别为t=-1．244、0．732、1．000，P〉0．05）。说明3种指标联合检测对于非小细胞肺癌的诊断具有重要价值。

The value of tumor markers in monitoring of non-small cell lung cancer

One hundred and four patients with non-small cell lung cancer (NSCLC) and 17 patients with benign lung lesions were enrolled in the study. Carcinoembryonic antigen ( CEA), neural specific enolaee (NSE) and cytokemtin 19 fragment (CYFRA21-1) in serum were detected by dectruchemiluminescence method before and after operation. The serum levels of three markers in preoperative NSCLC patients were significandy higher than those of benign pulmonary diseases group (t = 7. 930, 5.568, 6. 110, P <0. 05) ; but there were no significant differences between postoperative NSCLC patients and benign disease patients (t = - 0.034, 1. 242, 0.691, P > 0.05 ). There were significant differences in serum levels of CEA, NSE and CYFRA21-1 before and after operation in NSCLC group ( t = 5.419, 4.722, 5.779, P < 0.05 ) ; but not in benign pulmonary disease group ( t = - 1.244, 0.732, 1. 000, P >0.05). This study indicates that detection of serum CEA, NSE and CYFRA21-1 is of monitoring value for treatment of non-small cell lung cancer.